Corvus Pharmaceuticals Inc. ( (CRVS) ) has released its Q3 earnings. Here is a breakdown of the information Corvus Pharmaceuticals Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibitors for treating cancer and immune diseases, with its lead product candidate being soquelitinib. In its recent earnings report, Corvus Pharmaceuticals highlighted significant progress in its clinical trials, particularly with soquelitinib, which is being tested for atopic dermatitis and relapsed/refractory peripheral T cell lymphoma (PTCL). The company completed enrollment for a Phase 1 trial extension cohort for atopic dermatitis and is preparing to initiate a Phase 2 trial in early 2026. Additionally, the Phase 3 trial for PTCL is ongoing, with promising data from earlier phases being presented at a major hematology conference. Financially, Corvus reported a net loss of $10.2 million for the third quarter of 2025, a significant improvement from the previous year’s loss, and has cash reserves expected to fund operations into late 2026. Looking forward, Corvus remains focused on advancing its clinical programs and anticipates further data releases that could bolster its position in the biopharmaceutical industry.